Document:

QuickLinks
 -- Click here to rapidly navigate through this document

CONFIDENTIAL TREATMENT REQUESTED

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4),

200.83 and 240.24b-2  

 
  EXHIBIT 10.42    
  

 
  MEAD JOHNSON & COMPANY—HEALTHETECH
  STRATEGIC PARTNERSHIP AGREEMENT    
  

        This Strategic Partnership Agreement ("Agreement") is made and entered into as of this 8th day of
August, 2002 ("Effective Date") by and between HEALTHETECH, INC.
("HET"), a Delaware corporation having its principal place of business at 523 Park Point Drive, Golden, Colorado 80401 USA, and  MEAD JOHNSON &
COMPANY ("MJC"), a wholly-owned subsidiary of Bristol-Myers Squibb Company, a
Delaware corporation having its principal place of business at 345 Park Avenue, New York, New York, 10154, and MJC having its principal place of business located at 2400 W. Lloyd Expressway,
Evansville, Indiana 47721. 

RECITALS  

        WHEREAS, HET designs, develops and markets technologically advanced and proprietary handheld medical devices and
software for the measurement and monitoring of important health parameters. 

        WHEREAS, HET wishes to appoint MJC an authorized exclusive distributor of certain HET Products in the "Exclusive Markets" in the
"Territories", and MJC wishes to accept this appointment, subject to the terms and conditions of this Agreement. 

AGREEMENT  

        ACCORDINGLY, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties agree as follows: 

1.    DEFINITIONS. 

	1.1
	"Affiliate" means, with respect to a party, any person or entity that controls, is
controlled by, or is under common control with such party, where "control" means ownership of fifty percent (50%) or more of the outstanding voting securities (but only as long as such person or
entity meets these requirements).

	1.2
	"End User" means a person, company, or other legal entity that purchases a Product for
its own internal purposes and not for distribution or resale to, or use on behalf of, others. For the purposes of this definition, use of the Product by a healthcare professional to provide medical
and nutritional services to a patient of the professional or the institution will not constitute use on behalf of others.

	1.3
	"Exclusive Market" means those markets listed as Exclusive Markets on Exhibit C
hereto in which MJC shall have the exclusive right to sell the HET MedGemTM indirect calorimeter and its associated disposable Single-Use Breathing Inserts (disposable
mouthpieces or facemasks). Between the "Effective Date" and October 1, 2002, the "Exclusive Markets" shall be available to MJC only on a non-exclusive basis, and as of
October 1, 2002, the "Exclusive Markets" shall become exclusive to MJC.

	1.4
	"Excluded Market" means those markets listed on Exhibit C hereto in which MJC
shall refrain from directly or indirectly selling the HET MedGemTM indirect calorimeter and its associated disposable Single-Use Breathing Inserts (disposable mouthpieces or
facemasks); provided that MJC sales to cross functional groups which, in the reasonable belief of MJC, are not predominantly comprised of customers outside the Markets shall not necessarily be 

 

deemed
sales into Excluded Markets; provided further that if any question or dispute arises concerning any such situation, each of the parties will bring the matter to the attention of the other
party, and the parties shall negotiate in good faith a mutually agreeable resolution of such question or dispute. 

	1.5
	"HET Marks" means the trademarks, service marks and trade names of HET listed in
Exhibit D (as such list may be updated from time to time by HET upon notice to MJC).

	1.6
	"Intellectual Property Rights" means all present and future worldwide copyrights,
trademarks, trade secrets, patents, patent applications, contract rights, and any other intellectual property rights recognized by the law of each applicable jurisdiction.

	1.7
	"Markets" means the Exclusive Markets and Nonexclusive Markets collectively, and
specifically does not include the Excluded Markets, all as defined in Exhibit C herein, and as may be amended pursuant to section 2.2 herein.

	1.8
	"Nonexclusive Market" means those markets other than markets listed as Exclusive or
Excluded in Exhibit C in which MJC shall have the right to sell the HET MedGemTM indirect calorimeter and its associated disposable Single-Use Breathing Inserts
(disposable mouthpieces or facemasks) on a nonexclusive basis.

	1.9
	"Monitored Per-Measurement Fee Model" shall mean the anticipated MedGem
version where each metabolic measurement shall be subject to a payment per measurement and a Disposable Breathing Insert is supplied without additional charge with that measurement payment.

	1.10
	"Products" means only those devices and software of HET that are specifically listed
in the attached Exhibit A. HET may change the specifications, components, design, performance and appearance of any Product at any time. HET will
give MJC written notice of any such change, whereupon Exhibit A will be amended to reflect the change. If MJC believes, based upon a reasonable
commercial basis, that any notified change to a Product would adversely effect MJC's ability to succeed in selling that product, MJC shall have the right to exclude that specific product from Products
upon 30 days written notice to HET, and any purchase obligations herein specifically relating to that specific product shall end as of the date of the change to the specific product.

	1.11
	"Purchase Commitments" means the purchase commitments established by the parties in
accordance with this Agreement. The Purchase Commitments for the Term are set forth in Exhibit B.

	1.12
	"Single Use Breathing Insert" means the "disposable" facemask or mouthpiece that an individual breathes into during a MedGem metabolic
measurement or that is supplied as part of the "Monitored Per-Measurement Fee Model." This Insert is designed for one-time use and it is acknowledged by MJC that each Single
Use Breathing Insert is intended to be discarded at the end of a successful measurement.

	1.13
	"Software Products" means BalanceLogTM MedGem AnalyzerTM, and GlucoPilotTM.

	1.14
	"Term" shall have the meaning set forth in Section 10.1.

	1.15
	"Territories" shall mean the U.S.A., Canada and Puerto Rico.

	1.16
	"User Documentation" means the user documentation and instruction manuals furnished to MJC by HET for distribution along with the
Products. 

2.    LICENSES. 

	2.1
	Product Reseller. HET hereby grants to MJC a license to sell Products in the Exclusive and Nonexclusive Markets in the Territories for
the Term of this Agreement. MJC may not sell 

2

 

Products
to any other resellers or distributors without the written consent of HET. This license includes the nonexclusive rights to promote the Products to the persons defined as the Markets in the
Territories, to promote the Products to purchasing and other administrative personnel of the End User entities that actually purchase the Products for use by the persons in the Markets in the
Territories, and to sell the Products to the End User entities for use by the persons included in the Markets in the Territories. 

	2.2
	Conversion of Nonexclusive to Excluded Markets. Upon 30 days written notice to MJC and for no additional consideration, HET may
elect to amend the list of "Nonexclusive Markets" and "Excluded Markets" set forth on Exhibit C by moving any "Nonexclusive Market" to the list of "Excluded Markets." However, notwithstanding
the foregoing conversion right, specific identifiable practitioners who are part of the "Nonexclusive Market" to be converted, but who are included on MJC's "Hot List" on the Effective Date (as
attached as an addendum to Exhibit C shall) shall, as a group, continue to be deemed a "Nonexclusive Market" and there shall be no restriction on MJC's ability to continue selling to this
group. 

3.    OBLIGATIONS OF PARTIES  

	3.1
	Obligations of MJC.

	a)
	MJC
shall use reasonable efforts to develop sales of the Products in its areas of exclusivity. In furtherance thereof, MJC will fulfill obligations defined in  Exhibit F.

	b)
	MJC
will purchase Products per the quarterly schedule in Exhibit B. The parties use their commercially reasonable best efforts to
negotiate in good faith Target Purchase Commitments (covering not less than 4 prospective quarters) for the calendar quarters beyond those set forth in  Exhibit B not less than 90 days prior to
end of the last quarter for which Target Purchase Commitments are set forth on  Exhibit B.

	c)
	Agree
to comply with the Partner Branding Guidelines attached as Appendix 1 except where modified by this Agreement. In case of a
conflict between this Agreement and Appendix 1, the terms within this Agreement shall be controlling.

	d)
	At
such time as the Monitored Per-Measurement Fee Model is implemented, the parties agree that it will be the responsibility of MJC to ensure that adequate contractual
arrangements are in place with its customers and their buying organizations to ensure that MJC is being credited with all measurement sales for devices originally sold by MJC. 

	3.2
	Forecasts. Starting November 15, 2002 and by the 15thof the second month of each calendar quarter thereafter, MJC
will furnish HET with a rolling quarterly forecast, by month, of Product and Software Product sales by units for each Product and Software Product for the next twelve succeeding months. Each
forecast will be accompanied by a binding purchase order for the subsequent quarter. Except with respect to the Take-or-Pay Purchase Commitments, forecasts are otherwise not
binding on MJC. However, MJC acknowledges that compliance with this provision is a material obligation herein.

	3.3
	Reports. Not less than ninety (90) days before the start of each calendar year during the term of this agreement, MJC will
furnish HET with an annual marketing plan for the Products (detailing planned sales training, staffing, convention and trade show attendance, advertising, etc.). MJC will also give HET a written
summary of MJC's marketing initiatives for the Products, quarterly sales reports for the Products, and such other information as HET may reasonably request within fifteen (15) days after the
end of each calendar quarter. No later than the fifteenth (15th) work day of each month, MJC shall provide a written report to HET setting forth the number of units of Product and the
number of units of Single Use Breathing Inserts that were sold to MJC customers in the previous month. 

3

 

	3.4
	Obligations of HET. HET will:

	a)
	Refer
to MJC all inquiries for purchase of Products received from within the Markets and Territories;

	b)
	Keep
MJC informed of any Product complaints or adverse reactions that are, in HET's reasonable judgment, significant, and of all matters that are, in HET's reasonable judgment,
important concerning the quality and performance of Products;

	c)
	(i) Provide
MJC, at no charge, 10,000 MedGem Sales Brochures; and (ii) Supply MJC with the HET approved artwork and mechanicals required to support MJC production of its
own brochures and other promotional materials that shall be subject to review and approval by HET or MJC may request HET to produce brochures and other promotional materials for a fee of cost plus
[***]%. HET will review all MJC promotional materials promptly and will provide written approval or requests for change within ten (10) business days after
receipt of materials from MJC;

	d)
	Provide
to MJC the right of first negotiation to add new products offered by HET to the list of Products set forth on Exhibit A
hereto subject to the terms of this Agreement, including without limitation smaller, less expensive future generations of Products listed in  Exhibit A. This right of first negotiation shall consist
of HET notifying MJC of the availability of a proposed new product and its associated
proposed pricing, and providing MJC sixty (60) days after provision of a prototype of such product to MJC to evaluate and exclusively negotiate with HET pricing and Purchase Commitments
associated with the new product. In the event MJC elects not to include the new product to the list of Products, or in the event the parties are unable to come to a mutual agreement on the pricing and
Purchase Commitments associated with the new product terms within that sixty (60) day period, HET shall have the right to negotiate with other parties for distribution rights for that product
in the Markets defined herein. In addition to the right of first negotiation regarding all new products offered by HET, HET will provide to MJC the option to add to the list of Products any new
products offered by HET that are calorimeters, or breathing inserts or software for use with calorimeters. This option will consist of the same notice and prototype from HET as described above, and
the right of MJC to exercise the option by written notice to HET within sixty (60) days after receipt of the prototype. Upon exercise of such option, the new product will be added to the list
of Products provided in Exhibit A and will be subject to the terms of this Agreement. Any upgrades made to MedGem 1.0 may be subject to a maximum
price increase of no more than [***]%.

	e)
	HET
will deliver to MJC [***] Single Use Breathing Inserts per month for six consecutive months (beginning in any month after the Effective Date that MJC
shall designate in writing to HET) at no charge for use as demonstration units by MJC sales representatives.

	f)
	Provide
MJC, at no additional charge, 150 launch binders containing HET designated materials to support MJC launch activities for the Products.

	g)
	With
each MedGem 1.0 Kit purchased by MJC, provide MJC at [***], one BalanceLog CD per Kit containing a 14 day trial version of BalanceLog software for
Palm OS and Windows OS.

	h)
	Provide
MJC, at no additional charge, any information that MJC shall reasonably request in order for its sales force to be effective in promoting sales of the Products, including
without limitation copies of relevant information and practice guidelines from such groups as ADA, ASPEN and NASSO and information regarding insurance company guidelines 

4

 

for
reimbursement and information regarding reimbursement practices used by relevant healthcare professionals. 

	i)
	In
the event of a short supply situation for any of the Products, give priority to filling orders for MJC over any other HET partner or customer who has not entered into a minimum
commitments or take-or-pay agreement with HET.

	j)
	In
the event that the Monitored Per-Measurement Fee Model is implemented, HET will, at no cost to MJC, replace all Products that are not compatible with the Monitored
Per-Measurement Fee Model.

	k)
	At
such time as the Monitored Per-Measurement Fee Model is implemented, HET will ensure that adequate tracking and data management systems are in place in order for HET to
be able to identify sales of measurements with the individual devices through which those measurements will be administered. HET will make the necessary data available to MJC in order for MJC to
ensure that it is being credited with all measurement sales for devices originally sold by MJC, as contemplated by Section 3.1(d) above. 

4.    PURCHASE AND SALE OF PRODUCTS.  

	4.1
	Orders. MJC's purchase orders for Products are subject to the provisions of this Agreement. MJC shall submit a written purchase order
to HET for each order and shall submit all purchase orders for Products to be credited as purchased in a specified calendar quarter no later than the last day of the first month of that specified
calendar quarter, and HET shall transmit a written or verbal (telephone call) order confirmation within five (5) business days from receipt of the purchase order confirming the
Product quantities to be shipped and the estimated shipping date. Once a purchase order is accepted, HET will fill and ship orders in accordance with its customary procedures subject to Product
availability, however, HET specifically agrees to the firm delivery dates in section 3.1(b) for the initial purchase commitments specified in that section. HET shall make reasonable
efforts to fill MJC orders that are in excess of MJC's quarterly binding forecast required by Section 3.2. However, subject to Section 3.4(i) above, HET may allocate its output
according to its sole judgment if demand in excess of the MJC binding forecast exceeds its manufacturing capacity. HET may choose the mode of shipment and carrier unless otherwise specified in the
order.

	4.2
	Delivery. HET will deliver all Products sold to MJC F.O.B. point of origin. It is anticipated by the parties that MJC purchases will be
shipped to a MJC designated warehouse for subsequent MJC drop shipment to other MJC locations. Title to and all risk of loss of or damage or casualty to such Products will pass to MJC upon
initial delivery to the carrier. If Product is not shipped freight collect, MJC will reimburse HET on demand for all shipping charges, premiums for freight insurance, customs duties, import and export
fees, and transportation costs incurred by HET. HET may, at its option, select the freight forwarder. In addition, if no customs broker is specified, HET may, at its option, select a customs broker
for the specified shipment to a MJC designated location that is outside the United States. The obligations of MJC for freight and customs duties shall apply only to Products for which the point of
origin is in the United States.

	4.3
	Price. HET will sell Products to MJC under the Agreement at the prices set forth in  Exhibit E.
All prices are payable in United States currency unless provided otherwise on the applicable invoice.

	4.4
	Customer Orders and Shipments. HET shall provide (internally or outsourced) turn key warehousing, order processing and fulfillment,
shipping, invoicing, collection and record keeping with respect to MJC sales of Products to End Users. In addition, HET shall provide 

5

 

customer
support, regulatory tracking and maintenance as described in Exhibit G. In exchange for such services for all Products, MJC shall pay
to HET [***]% of the End User gross sales price of each batch of Single Use Breathing Inserts purchased by MJC customers reflected on the invoice for each such sale. In
addition, HET shall provide to MJC at no additional cost such reports in such format as MJC shall reasonably request to enable it to track information regarding its sales of Products and shall permit
MJC reasonable access to HET records regarding such sales for MJC's audit purposes. 

	4.5
	Payment. Unless otherwise specified in the applicable order and agreed to in writing by HET, MJC will pay each of HET's invoices within
fifty (50) days after the receipt of the invoice.

	4.6
	Interest. Any amount not paid when due will be subject to finance charges at the rate of one half of one percent (0.5%) per month or
the maximum rate permitted by applicable law, whichever is less, determined and compounded on a daily basis from the date due until the date paid. Payments of such finance charges will not excuse or
cure MJC's breach or default for late payment. If HET retains a collection agency, attorney or other person or entity to collect overdue payments, all collection costs,
including but not limited to reasonable attorney's fees, will be payable by the prevailing party, including but not limited to reasonable attorney's fees of the prevailing party will be payable by the
other party.

	4.7
	Defective Product Returns. Authorization is required for all defective Product returns pursuant to the product warranty and a returned
materials authorization ("RMA") number must be obtained from HET prior to returning Product under warranty to HET. Authorization for defective Product
returns shall not be unreasonably withheld by HET. 

5.    ADDITIONAL EFFORTS. 

	5.1
	Insurance Reimbursement. MJC agrees to use commercially reasonable efforts to assist HET in identifying and qualifying opportunities to
obtain medical insurance reimbursement for the use of the MedGem to measure metabolic rates.

	5.2
	Nutrition Monitoring Program. HET shall work with MJC to reasonably develop a nutrition-monitoring program for use, among other things,
in medical nutrition therapy. 

6.    CONFIDENTIALITY. 

	6.1
	Confidential Information. Each party (the "Disclosing Party") may from time to time
during the term of this Agreement disclose to the other party (the "Receiving Party") certain information regarding the Disclosing Party's business,
including technical, marketing, financial, employee, planning, and other confidential or proprietary information ("Confidential Information"). The
Disclosing Party will mark all Confidential Information in tangible form as "confidential" or "proprietary" or with a similar legend. The Disclosing Party will identify all Confidential Information
disclosed orally as confidential at the time of disclosure. Regardless of whether so marked or identified, however, any information that the Receiving Party knew or should have known, under the
circumstances, was considered confidential or proprietary by the Disclosing Party, will be considered Confidential Information of the Disclosing Party.

	6.2
	Protection of Confidential Information. The Receiving Party will not use any Confidential Information of the Disclosing Party for any
purpose not expressly permitted by this Agreement, and will disclose the Confidential Information of the Disclosing Party only to the employees or contractors of the Receiving Party who have a need to
know such Confidential Information for purposes of this Agreement and who are under a duty of confidentiality no less restrictive than the Receiving Party's duty hereunder. The Receiving Party will
protect the Disclosing Party's Confidential Information from
unauthorized use, access, or disclosure in the same manner as the Receiving Party protects its own confidential or proprietary information of a similar nature and with no less than reasonable care. 

6

  

	6.3
	Exceptions. The Receiving Party's obligations under Section 6.2 with respect to any Confidential Information of the Disclosing
Party will terminate if and when the Receiving Party can document that such information: (a) was already known to the Receiving Party at the time of disclosure by the Disclosing Party;
(b) is disclosed to the Receiving Party by a third party who had the right to make such disclosure without any confidentiality restrictions; (c) is, or through no fault of the Receiving
Party has become, generally available to the public; or (d) is independently developed by the Receiving Party without access to, or use of, the Disclosing Party's Confidential Information. In
addition, the Receiving Party will be allowed to disclose Confidential Information of the Disclosing Party to the extent that such disclosure is (i) approved in writing by the Disclosing Party,
(ii) necessary for the Receiving Party to enforce its rights under this Agreement; or (iii) required by law or by the order or a court of similar judicial or administrative body,
provided that the Receiving Party notifies the Disclosing Party of such required disclosure promptly and in writing and cooperates with the Disclosing Party, at the Disclosing Party's reasonable
request and expense, in any lawful action to contest or limit the scope of such required disclosure.

	6.4
	Return of Confidential Information. The Receiving Party will either, at its option, return to the Disclosing Party or destroy all
Confidential Information of the Disclosing Party in the Receiving Party's possession or control and permanently erase all electronic copies of such Confidential Information promptly upon the written
request of the Disclosing Party or the expiration or termination of this Agreement, whichever comes first. At the Disclosing Party's request, the Receiving Party will certify in writing signed by an
officer of the Receiving Party that it has fully complied with its obligations under this Section 6.4

	6.5
	Confidentiality of Agreement. Neither party will disclose any terms of this Agreement to anyone other than its Affiliates, attorneys,
accountants, and other professional advisors under a duty of confidentiality except (a) as required by law or regulation (including securities listing agreements) (b) pursuant to a
mutually agreeable press release or (c) in connection with a proposed merger, financing, or sale of such party's business (provided that any third party to whom the terms of this Agreement are
to be disclosed signs a confidentiality agreement reasonably satisfactory to the other party to this Agreement). Each party will use commercially reasonable efforts to notify the other in advance of
its intention to so disclose and, in determining the timing and manner of such disclosure, will take into consideration the reasonable requests of the other party. 

7.    PROPRIETARY RIGHTS. 

	7.1
	Product Ownership. The Products and all worldwide Intellectual Property Rights therein, are the exclusive property of HET and its
suppliers. All rights in and to the Products not expressly granted to MJC in this Agreement are reserved by HET and its suppliers. Nothing in this Agreement will be deemed to grant, by implication,
estoppel, or otherwise, a license under any of HET's existing or future patents; HET agrees that it will not assert any of its rights under such patents against MJC or its Affiliates based upon the
use, distribution, and sublicensing by MJC or its Affiliates of the Products as permitted by this Agreement.

	7.2
	Trademark License. Subject to the terms and conditions of this Agreement, HET grants to MJC and those of its Affiliates which agree in
writing to be bound by the terms of this Agreement a non-exclusive, non-transferable (except as permitted under Section 12.3 (Assignment), revocable,
royalty-free license (without the right to grant sublicenses) to use and reproduce the HET Marks solely in connection with marketing the Products in the Markets. MJC agrees to state in
appropriate places on all materials using the HET Marks that the HET Marks are trademarks of HET and to include the symbol TM or ® as appropriate. HET grants no rights in the
HET Marks other than those expressly granted in this Section 7.2. MJC acknowledges HET's exclusive ownership of the HET Marks. MJC agrees not to take any 

7

 

action
inconsistent with such ownership and to cooperate, at HET's request and expense, in any action (including the conduct of legal proceedings) which HET deems necessary or desirable to establish
or preserve HET's exclusive rights in and to the HET Marks. MJC will not adopt, use, or attempt to register any trademarks or trade names that are confusingly similar to the HET Marks or in such a way
as to create combination marks with the HET Marks. MJC will provide HET with samples of all products and materials that contain the HET Marks prior to their public use, distribution, or display for
HET's quality assurance purposes and will obtain HET's written approval before such use, distribution, or display. At HET's request, MJC will modify or discontinue any use of the HET Marks if HET
determines that such use does not comply with HET's then-current trademark usage policies and guidelines. HET shall not make any use of any name or trademark of MJC nor of any of MJC's
products for any purpose without MJC's express prior written approval, except as otherwise stated in Section 9.5 of this Agreement. 

	7.3
	Assignments. At the end of the Term, MJC will assign to HET or such other person or entity as HET may designate all rights,
registrations, reservations, licenses, permits and similar items made or obtained by MJC relating to the Products, the Trademarks, or any other proprietary rights of HET. 

8.    WARRANTIES, REMEDIES AND DISCLAIMERS. 

	8.1
	Product Warranty. HET warrants to and for the benefit of MJC only that all Products, as delivered pursuant to Section 4.2, will
be free from material defects in materials and workmanship in the course of normal use in compliance with the instructions in the User Documentation. This warranty shall apply for a period of fifteen
(15) months after delivery to the initial MJC designated location as provided in
Section 3.1 or 4.2 or twelve (12) months after commercial sale to an End-User customer, whichever is shorter, for MedGem devices. For Single Use Breathing Inserts the
warranty period shall be ninety (90) days after commercial sale to an End User, and for software, the warranty period shall be ninety (90) days after commercial sale to an End User (the
"Device Warranty Period"). In the event a Product is subject to warranty replacement, HET will exchange out the subject Product as quickly as reasonably
possible, in any event not to exceed fifteen (15) business days.

	8.2
	Limited Acceptance Remedy. If, on delivery, all or any part of a Product is nonconforming, then MJC's sole remedy shall be to exchange
such Product with another, conforming Product unit or, at HET's option, receive a refund of all amounts paid to HET for such nonconforming Product. Any such exchange of a Product shall be in
accordance with HET's return materials authorization process above.

	8.3
	Warranties Made by MJC. MJC will not make or publish any representations, warranties, or guarantees on behalf of HET or its suppliers
concerning the Products that are inconsistent with any warranties made by HET concerning the Products.

	8.4
	Warranties by Both Parties. Each party represents and warrants that it has full power and authority to enter into and perform this
Agreement, and the person signing this Agreement on such party's behalf has been duly authorized and empowered to enter into this Agreement. Each party represents and warrants it is free to enter into
and perform this Agreement without thereby being in breach of or default under the terms of any other contract, commitment or understanding.

	8.5
	Disclaimer. EACH OF HET AND MJC ACKNOWLEDGE THAT IT HAS RELIED ON NO WARRANTIES OTHER THAN THE EXPRESS WARRANTIES IN THIS AGREEMENT.
NEITHER HET NOR MJC WILL, UNDER ANY CIRCUMSTANCE, BE LIABLE TO THE OTHER PARTY, OR ANY END USER OR TRANSFEREE FOR COSTS OF PROCUREMENT OF SUBSTITUTE PRODUCTS OR SERVICES, LOST 

8

 

PROFITS
OR ANY OTHER SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT EVEN IF THE PARTY FROM WHICH SUCH DAMAGES ARE SOUGHT HAS BEEN NOTIFIED OF THE POSSIBILITY OF SUCH
DAMAGES. 

	8.6
	Indemnification by HET. HET shall indemnify MJC against, and HET will defend at its own expense, any action against MJC brought by a
third party to the extent that the action is based upon a claim (a) of bodily injury (including death) or damage to personal property to the extent directly caused by negligence in the design
or manufacture of the Products or (b) that a Product infringes any patents, copyrights or misappropriates any trade secrets of a third party or that the HET Marks, when used by MJC in
accordance with this Agreement, infringe any trademark rights of a third party. HET will pay those costs and damages finally awarded against MJC in any such action that are specifically attributable
to such claim or those costs and damages agreed to in a monetary settlement of such action providing that MJC notifies HET promptly in writing of such action, MJC gives HET sole control of the defense
thereof and any related settlement negotiations, and MJC provides full
cooperation and, at HET's reasonable request and expense, assisting in such defense. Notwithstanding the foregoing, HET will have no obligation under this Section or otherwise with respect to
any infringement claim based upon (i) any use, reproduction, or distribution of the Products by MJC or any of its Affiliates or End Users (except where MJC has taken commercially reasonable
steps to prevent End Users from so doing) in a manner that is inconsistent with the written HET instructions for use accompanying the Product (ii) any use of the Products by MJC or any of its
Affiliates or End Users (except where MJC has taken commercially reasonable steps to prevent End Users from so doing) in combination with other products, equipment, software, or data that is not
either supplied by HET or intended by HET to be used with the Products, or (iii) any modification of Products by MJC or any of its Affiliates or End Users (except where MJC has taken
commercially reasonable steps to prevent End Users from so doing). 

9.    OTHER OBLIGATIONS OF MJC. 

	9.1
	No Unauthorized Warranties. MJC will not make or extend on behalf of HET any written or oral warranty in respect of any of the Products
except as may be contained in sales literature or brochures that are published or approved in writing by HET. MJC will not advise, perform or demonstrate any use or application of any Product that is
not specifically approved in writing by HET. MJC will not impair the sterility or integrity of the Products while they are in MJC's custody.

	9.2
	Compliance With Laws. MJC represents and warrants that is thoroughly familiar with applicable laws, ordinances, regulations other
governmental requirements concerning the importation, handling, marketing, sale, demonstration, use and distribution of Products in the Markets. MJC will comply with all laws, ordinances, regulations
and other governmental requirements applicable to its business and to MJC's involvement in the importation, handling, marketing, sale, demonstration, use and distribution of Products pursuant to this
Agreement. MJC will provide to HET an accurate English translation of any applicable foreign language laws, ordinances, regulations and other governmental requirements referenced herein and any other
related documents as may be reasonably requested by HET. Notwithstanding the foregoing, HET shall bear responsibility for compliance with laws as a manufacturer of the Products including those
Products manufactured as medical devices.

	9.3
	Insurance. During the Term, MJC will maintain liability insurance coverage issued by a responsible insurer satisfactory to HET as an
additional insured and afford HET not less than twenty (20) days advance notice of cancellation or material change in the policy. Upon HET's request, MJC will provide a certificate of insurance
from the insurer certifying that coverage is in place. Also during the Term, HET will maintain $2 million per occurrence liability 

9

 

insurance
coverage issued by a responsible insurer and list MJC as an additional insured on such policy and afford MJC not less than twenty (20) days advance notice of cancellation or material
change in the policy. Upon MJC's request, HET will provide a certificate of insurance from the insurer certifying that coverage is in place. 

	9.4
	Noncompete. MJC warrants and agrees that it does not now and will not during the Term, without the prior written consent of HET,
directly or indirectly market, sell or promote any product in the Markets that measures resting metabolic rates or oxygen consumption, other than the Products. MJC further warrants and agrees that it
will not manufacture or cause to have manufactured, nor purchase from a third party, any Single Use Breathing Inserts that are not approved in writing by HET. HET warrants and agrees that it shall not
authorize any other party to sell the Products in the Market in the Territories. 

10.  TERM AND TERMINATION. 

	10.1
	Term. Unless earlier terminated pursuant to Sections 10.2 or 10.3 the initial term of this Agreement will begin on the Effective Date
and expire on June 30, 2004 (the "Term"). The Term can be extended by mutual written agreement by the parties.

	10.2
	Termination by HET. Upon the occurrence of any of the following, HET may terminate the Agreement by giving MJC written notice of such
termination:

	a)
	Any
assignment or attempted assignment or transfer, by operation of law or otherwise other than in accordance with the provisions of this Agreement by MJC;

	b)
	The
failure of MJC to make any payment when due, subject to HET providing MJC written notice of such failure to make payment and MJC not curing such deficiency within ten
(10) days from receipt of such notice;

	c)
	MJC
directly or indirectly markets, sells or promotes any product in the Markets that competes with any Product or has a significant financial interest in any company or individual
that is manufacturing, assembling, producing, marketing, selling or distributing any product that competes with any Product;

	d)
	MJC
knowingly sells Products directly or indirectly to customers located outside the Markets; provided that no termination shall be claimed as a result of MJC sales to cross functional
groups which, in the reasonable belief of MJC, are not predominantly comprised of customers outside the Markets;

	e)
	The
insolvency of MJC, the filing of a petition in bankruptcy by or against MJC, the appointment of a receiver for MJC or MJC's property, the execution of an assignment by MJC of all
or substantially all of its assets for the benefit of its creditors, or the conviction of MJC or any principal or manager of the MJC for any crime tending to adversely affect the ownership or
operation of business;

	f)
	The
failure of MJC to meet the Target Purchase Commitments provided in Exhibit B, subject to the right to cure set forth therein, or the parties fail to agree on future Target
Purchase Commitments as contemplated in Section 3.1(b).

	g)
	Other
than as set forth in Section 10.2 (a) through (e), any failure by MJC to perform any of its obligations under this Agreement where such failure is not cured to the
reasonable satisfaction of HET within thirty (30) days after written notice thereof by HET to MJC. 

10

 

	10.3
	Termination by MJC. Upon the occurrence of any of the following, MJC may terminate the Term by giving HET written notice of such
termination:

	a)
	The
filing of a petition in bankruptcy by or against HET, the appointment of a receiver for HET or HET's property, or the execution of an assignment by HET of all or substantially all
of its assets for the benefit of its creditors; or

	b)
	Any
failure by HET to perform any of its obligations under this Agreement where such failure is not cured to the reasonable satisfaction of MJC within thirty (30) days after
written notice thereof by MJC to HET. 

	10.4
	Termination By Mutual Consent. The parties may, at any time and without cause, terminate this Agreement by mutual written consent.

	10.5
	Effect of Termination. Any termination pursuant to Section 10.2 or 10.3 will be without prejudice to any other right or remedy
afforded to either party under this Agreement or any applicable law (e.g., in the case of any breach or default by the other party), and will not affect any rights or obligations which have arisen
prior to the date of such termination. Termination of the Agreement shall not relieve the parties of any obligation or liability arising prior to such termination, including the obligation to maintain
the confidentiality of certain information as referenced in Section 6 above. In the event of termination, MJC will:

	a)
	Not
have any further right to market, sell or distribute Products in the Markets in the Territories;

	b)
	Furnish
HET with such information relating to the status of the marketing, sale or distribution of Products in the Markets as HET may reasonably request (including, but not limited to,
information as to calls or the status of any negotiations for the sale of the Products);

	c)
	Will
return to HET any Products, sales materials, manuals, price lists, and mailing lists provided by HET to MJC for demonstration, promotional, or marketing purposes; and

	d)
	Will
return to HET any Products, which have not been committed for sale to a customer. HET will repurchase these Products at MJC's cost. 

	10.6
	Standards of Performance. The parties agree and acknowledge that the standards of performance imposed on it by this Agreement
(including Minimum Purchase Commitments) are reasonable and that any failure on its part to comply fully with all of the terms and conditions set forth in this Agreement shall constitute a material
breach and good cause for termination of this Agreement.

	10.7
	Acknowledgment. Any expiration or termination of the Term will be final and absolute. Both parties waive any right, either express or
implied by applicable law or otherwise, to renewal of this Agreement or to any damages or compensation for any expiration or termination of the Term in accordance with this Section 10. Each of
the parties have considered the possibility of such expiration or termination and the possibility of loss and damage resulting there from in making expenditures pursuant to the performance of this
Agreement. It is the express intent and agreement of the parties that neither will be liable to the other for damages or otherwise by reason of the expiration or termination of the Term as provided
for herein.

	10.8
	Survival. Sections, 6, 7, 8, 10.4, 11, and 12.5-12.13 will survive expiration or termination of this Agreement for any
reason. 

	11.
	LIMITATION OF LIABILITY. HET'S AND MJC'S LIABILITY (WHETHER IN TORT, CONTRACT OR OTHERWISE AND NOTWITHSTANDING ANY FAULT, NEGLIGENCE
(WHETHER ACTIVE, PASSIVE OR IMPUTED), PRODUCT LIABILITY, OR STRICT LIABILITY OF HET) UNDER THIS AGREEMENT OR WITH REGARD TO ANY 

11

 

PRODUCTS
OR OTHER ITEMS FURNISHED UNDER THIS AGREEMENT WILL IN NO EVENT EXCEED THE COMPENSATION PAID (OR PAYABLE AS A RESULT OF THE TAKE-OR-PAY COMMITMENTS SET FORTH IN
EXHIBIT A HERETO) TO HET UNDER THIS
AGREEMENT. IN NO EVENT WILL HET OR MJC BE LIABLE FOR ANY INDIRECT, INCIDENTAL SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF ITS PERFORMANCE OR NONPERFORMANCE OF THIS AGREEMENT OR THE USE OF,
INABILITY TO USE, OR RESULTS OF USE OF ANY PRODUCTS. THIS SECTION SHALL NOT APPLY TO LIABILITY FOR INDEMNIFICATION UNDER SECTION 8 OF THIS AGREEMENT. 

12.  MISCELLANEOUS. 

	12.1
	Independent Contractor. Each of MJC and HET is an independent contractor and not an agent, employee, franchise or partner of the
other, and is acting in the ordinary course of business. Neither HET nor MJC has any authority to, and will not create or assume any obligation, express or implied, on behalf of the other. HET and MJC
shall each be responsible for all taxes and payments concerning itself, its employees and its sales representatives. This Agreement does not create or evidence any joint venture or partnership of the
parties.

	12.2
	Force Majeure. Neither party will be liable for, or be considered to be in breach of or default under this Agreement on account of,
any delay or failure to perform as required by this Agreement (other than for payments owed) as a result of any cause or condition beyond such party's reasonable control.

	12.3
	Assignment. Neither HET nor MJC may assign or transfer, by operation of law or otherwise, any of its rights under this Agreement or
delegate any of its duties under this Agreement to any third party other than its Affiliates without the other party's prior written consent. Any attempted assignment or transfer in violation of the
foregoing will be void.

	12.4
	Notice. Notices or consents under this Agreement will be in writing and delivered personally or, if mailed, will be sent certified
mail, return receipt requested, or facsimile or overnight express service, if addressed to the recipient's address set forth on the signature page of this Agreement, or in either case to such
other address as may be established by notice to the other party. Notice will be effective only upon actual receipt.

	12.5
	Nonwaiver. The failure of either party to insist upon or enforce strict performance of any of the provisions of this Agreement or to
exercise any rights or remedies under this Agreement will not be construed as a waiver or relinquishment to any extent of such party's right to assert or rely upon any such provisions, rights or
remedies in that or any other instance; rather, the same will be and remain in full force and effect.

	12.6
	Interpretation. The English language of the Agreement will govern any interpretation of or dispute regarding the terms of this
Agreement. Paragraph captions are for convenience of reference and do not alter or limit the terms of this Agreement.

	12.7
	Remedies. Except as provided in Section 8 (Warranties, Remedies and Disclaimers) the parties' rights and remedies under this
Agreement are cumulative. MJC acknowledges that the Products contain valuable trade secrets and proprietary information of HET, that any actual or threatened breach of Section 7.2 (Trademark
License) or Section 6 (Confidentiality) will constitute immediate, irreparable harm to HET for which monetary damages would be an inadequate remedy, and that injunctive relief is an appropriate
remedy for such breach. If MJC continues to distribute the Products after its right to do so has terminated or expired, HET will be entitled to immediate injunctive relief without the requirement of
posting bond, including an order directing that any Products that MJC attempts to import into any country or territory be seized, impounded, and destroyed by customs officials. If any legal action is
brought to enforce this Agreement, the prevailing party will be entitled to receive its attorneys' fees, court costs, and other collection expenses, in addition to any other relief it may receive. 

12

  

	12.8  	 	Severability. If any provision of this Agreement is unenforceable, such provision will be changed and interpreted to accomplish the objectives of such provision to the greatest extent possible
under applicable law and the remaining provisions will continue in full force and effect. Without limiting the generality of the foregoing, MJC agrees that Section 11 (Limitation of Liability) will remain in effect notwithstanding the
unenforceability of any provision in Section 8 (Warranties, Remedies and Disclaimers).
	
12.9  	
 	

Construction. As used in this Agreement, the word "including" means "including but not limited to."
	
12.10	
 	

Counterparts. This Agreement may be executed in counterparts, each of which will be considered an original, but all of which together will constitute the same instrument.
	
12.11	
 	

Arbitration. The parties agree to make every reasonable effort to amicably settle any controversy between them relating to the terms and conditions and subject matter of this Agreement. In the event that the parties are unable
to reach an amicable settlement regarding any controversy relating to the terms, conditions or subject matter of this Agreement, the parties agree that, within 30 days following written notice of a request for arbitration served by one of the
parties upon the other, they shall submit such controversy to a single, independent, unbiased arbitrator. The arbitration will be carried out in accord with the rules of the American Arbitration Association at its offices in Chicago, Illinois.
Discovery will be carried out in accord with the Federal Rules of Civil Procedure and, should said rules be in conflict with any of the rules of the American Arbitration Association, the Federal Rules shall prevail. In the event the parties
cannot agree upon a single arbitrator within 20 days following a written request for arbitration, the arbitrator will be selected by the American Arbitration Association. The decision of the arbitrator will be final and binding upon both
parties. Upon application by either party, the decision of the arbitrator may be entered as a final award or judgment by any court of competent jurisdiction in the United States of America.
	
12.12	
 	

Governing Law; Venue. The rights and obligations of the parties under this agreement shall be governed in all respects by the laws of the State of Colorado exclusively; as such laws apply to contracts between Colorado
residents performed entirely within Colorado. MJC agrees that upon HET's request, all disputes arising hereunder shall be adjudicated in the state and federal courts having jurisdiction over disputes arising in Denver, Colorado, and MJC hereby agrees
to consent to the personal jurisdiction of such courts.
	
12.13	
 	

Entire Agreement. This Agreement contains the entire agreement, and supersedes any and all prior agreements, between the parties with regard to the appointment of MJC as a distributor of Products and MJC's purchase and sale of
Products. HET will not be bound be, and specifically objects to, any terms, conditions, or other provisions that are different from or in addition to the provisions of the Agreement (whether or not it would materially alter this correspondence, or
otherwise. Without limiting the generality of the foregoing, any printed terms, conditions of other provisions that are included in or accompany any of the MJC's orders for Products under this Agreement will not apply to be binding on HET. This
Agreement may not be waived, amended or rescinded except by a writing signed by the party to be charged thereby.
	
12.14	
 	

Publicity. Neither party shall issue any press release regarding this Agreement or the relationship between the parties unless the release is approved in advance by the other party in writing.

[signature page follows]

13

 

        IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written. 

	
HEALTHETECH, INC.:	
 	

MEAD JOHNSON & COMPANY:
	

By:	

/s/  JAMES R. MAULT      
	
 	

By:	

/s/  RANDALL K. ALSMAN      

	 	James R. Mault, MD

Chairman and CEO

523 Park Point Drive

Golden, CO 80401

Fax: 303-526-5186	 	 	Randall K. Alsman

President, U.S. and Global

    Business Support

2400 West Lloyd Expressway

Evansville, IN 47721-0001

Fax: 812-429-8866

14

 
 
 

Exhibit A
  PRODUCT LIST    
  

	1.
	Products 

MedGemTM
1.0 Kit*

Disposable Mouthpieces

Disposables Masks; small, medium, large 

Extras
or Spare Parts:

MedGem AC/DC Power Adapter

MedGem Battery Pack (when available)

MedGem Manual

MedGem Video Guide

Nose clips

Nose clips with foam pads 

	2.
	Software
Products: 

MedGem
Analyzer Software Kit**

BalanceLogTM Software for Windows

BalanceLog Software for Palm OS

BalanceLog Software Palm & Windows

GlucoPilotTM Software for Palm OS 

	*
	Includes:
MedGem Indirect Calorimeter Unit, AC/DC Medical Grade Power Supply (1), Hard Facemask Shell MedGem (1), Medium Facemask (1), Disposable (1),
Mouthpiece Disposable (1) MedGem, Flow Tube (1), Nose clip (1), Quick Start Guide, MedGem Operator's Manual, MedGem Video Guide, and Carrying case. BalanceLog Software for Palm & Windows

	**
	Includes:
MedGem Analyzer Software CD, Quick Start Guide for MedGem Analyzer Software, Serial Data Cable. 

        Note:
The parties can add new Products as they become available by mutual written agreement pursuant to Section 3.4(d). 

15

 
 
 

Exhibit B
  Purchase Commitments    
  

Take-or-Pay Purchase Commitments  

        MJC Take-or-Pay Purchase Commitments for Q1, 2003 through Q3, 2003: 

	MedGem Devices
	 
	Calendar Quarter
	 	Minimum Units per Quarter
	 
	Q1, 2003	 	[***]	 
	Q2, 2003	 	[***]	 
	Q3, 2003	 	[***]	*

	Disposable Single Use Breathing Inserts

	Calendar Quarter
	 	Minimum Units per Quarter

	Q1, 2003	 	[***]
	Q2, 2003	 	[***]
	Q3, 2003	 	[***]

	*
	Comprised
of [***] units at $[***] and remaining [***] units at
$[***] (pricing set forth on Exhibit E specifies first [***] at $[***];
[***] + [***] + [***] = [***]). 

        For
the sake of clarity, the parties agree that the provisions of Section 11 of this Agreement regarding limitation of liability shall apply specifically to the
Take-or-Pay Commitments set forth in this Exhibit B. 

16

 

Target Purchase Commitments  

        In addition to the Take-or-Pay Purchase Commitments above, the parties agree to the following Target Purchase Commitments for the quarters
Q3, 2003 through Q2, 2004. MJC agrees to use reasonable commercial efforts to meet or exceed these Target Purchase Commitments. If MJC fails to meet these Target Purchase Commitments for any
particular quarter, HET may at its sole discretion serve notice to MJC (i) terminating this Agreement under Section 10.2 hereof or (ii) converting any or all of the "Exclusive
Markets" listed on Exhibit C to "Non-exclusive Markets" for the remaining Term or this Agreement, provided that any such termination or conversion shall be effective as of the last
day of the quarter following the quarter in which MJC failed to meet its Minimum Purchase Commitments (the "Cure Quarter"). Notwithstanding the foregoing, no such termination or conversion shall be
effectuated in the event that, during the Cure Quarter, MJC meets its Minimum Purchase Commitments for such Cure Quarter and, in addition, submits firm purchase orders for Products in an amount not
less than the shortfall in its Minimum Purchase Commitments from the previous quarter. For the sake of clarity, the parties agree that the remedies listed above under (i) and (ii) shall
be the sole remedies that HET shall have in the event of failure by MJC to meet the Target Purchase Commitments set forth on this Exhibit B. 

	MedGem Devices
	 
	Calendar Quarter
	 	Minimum Units per Quarter
	 
	Q3, 2003	 	[***]	*
	Q4, 2003	 	[***]	 
	Q1, 2004	 	[***]	 
	Q2, 2004	 	[***]	 

	Disposable Single Use Breathing Inserts

	Calendar Quarter
	 	Minimum Units per Quarter

	Q3, 2003	 	[***]
	Q4, 2003	 	[***]
	Q1, 2004	 	[***]
	Q2, 2004	 	[***]

	*
	Includes
(i.e., is not in addition to) the [***] units in included in Q3, 2003 Take-or-Pay Purchase
Commitment. 

17

 
 
 

Exhibit C
  MARKETS IN TERRITORIES    
  

"Exclusive
Markets" shall include: 

	•
	All
hospital-based dietitians

	•
	All
physicians and osteopaths specializing in:

	•
	Oncology

	•
	Hospital
based Nutrition Support Services

	•
	Obstetrics

	•
	Gynecology

	•
	Pediatrics

	•
	Bariatric
surgery 

"Nonexclusive
Markets" shall include: 

	•
	Non-hospital
based Dietitians

	•
	Internal
Medicine Physicians

	•
	Family
Practice Physicians

	•
	General
Practice Physicians

	•
	Geriatric
Medicine Physicians

	•
	Gastroenterologists

"Excluded
Markets" shall include: 

	•
	Cardiologists

	•
	Endocrinologists

	•
	Pulmonologists

	•
	Respiratory
Therapists

	•
	Rehabilitation
physicians

	•
	Rehabilitation
facilities

	•
	Physical
therapists

	•
	All
current and future HealthSouth facilities (whether owned, managed, operated or branded as such) 

"Hot
List" referenced in Section 2.2 of this Agreement attached as addendum to this Exhibit C 

18

  

 
 

Exhibit D
  TRADEMARKS    
  

Trademarks
and trade names ("Marks") of HET: 

        HealtheTech
(name and stylized mark) 

        Your
Body Is Talking. Listen. 

        BalanceLog 

        Calorie
Checkbook 

        Listen
To Your Body 

        MedGem

        MedGem
Analyzer 

        GlucoPilot

19

 
 
 

Exhibit E
  PRICE LIST    
  

(All prices are MJC prices in U.S. Dollars)  

(a)  MedGemTM 1.0 Kit:  

        $[***]/each for first [***] MedGem devices purchased by MJC. 

        After
[***] units price shall be $[***]/each. 

        Note: The anticipated future Monitored Per-Measurement Fee MedGem Model, when available, shall be provided to MJC at the same unit
price.

(b)  Single Use Breathing Inserts for MedGem:  

        $[***] each 

        Disposable
Masks are available in size small, medium and large. Each box contains one size. This pricing shall apply to per-measurement fees upon HET adoption into the
Products of the Monitored Per-Measurement Fee Model. 

(c)  Software:  

	BalanceLogTM Software for Windows	 	$[***] each
	BalanceLog Software for Palm OS	 	$[***] each
	BalanceLog Software for Palm & Windows	 	$[***] each
	GlucoPilotTM Software for Palm OS	 	$[***] each
	MedGem Analyzer Software Kit	 	$[***] each

(d)  Accessories/Extras:  

	MedGem AC/DC Power Adapter	 	$[***] each
	MedGem Battery Pack (when available)	 	$[***] each
	MedGem Manual (Extras)	 	$[***] each
	MedGem Video Guide	 	$[***] each
	Nose clips (Extras)	 	$[***] each
	Nose clips w/ foam pads	 	$[***] each

20

 
 
 

EXHIBIT F
  MJC OBLIGATIONS    
  

        MJC shall, for the Term of this Agreement, perform the following obligations and shall cause any End User to perform the following obligations where applicable,
for the Term of this Agreement: 

	(i)
	Provide
for appropriate End User training sufficient to enable use and promotion of metabolic measurement services using the MedGem in compliance with
the operating instructions and any training provided by HET to MJC, and proper use of BalanceLog and GlucoPilot.

	(ii)
	Refer
End Users to HET for Level One Customer Support, defined as supporting frequently asked questions and troubleshooting, to all MJC End Users
during regular HET customer hours throughout the Hardware Warranty Period or Software Warranty Period, as the case may be. The products supported by HET Customer Support obligations under this
Agreement include the MedGem metabolic measurement devices and the HET BalanceLogTM and GlucoPilot software.

	(iii)
	Not
knowingly incur any liability on behalf of HET, nor in a any way pledge or purport to pledge HET's credit; nor describe or hold itself out as an
employee of HET; nor describe itself other than as a distributor of the Products and Software Products; nor make any claims (medical or otherwise) inconsistent with written product manuals or HET
provided MedGem distributor training.

	(iv)
	MJC
shall not use any non-HET approved Single Use Breathing Inserts with the MedGem metabolic measurement device. MJC acknowledges that use
of any non-HET approved breathing insert (mouthpiece or facemask) with the MedGem device voids the warranty for such device and may cause the device to operate inaccurately.

	(v)
	Acknowledge
that the Single Use Breathing Inserts are disposable components and are not intended for re-use and that any re-use
may present a risk of transmission of infectious or communicable diseases. MJC agrees it shall instruct all of its End Users not to re-use the Single Use Breathing Inserts, or otherwise
misuse the MedGem devices in a way that is not consistent with HET provided instructions for use located in the MedGem Operator's Manual.

	(vi)
	Provide
appropriate recommendations and counseling for use of each Product sold by MJC.

	(vii)
	In
coordination with the appropriate MJC sales employee, allow HET access to visit any MJC End User location during normal business hours or
accompany any MJC employee detailing, selling or explaining MedGem to any End User and at HET's sole expense to conduct a review of the End-User facilities and their Products' use and if
applicable, make suggestions for improvement based upon HET's experience with the Products.

	(viii)
	Allow
HET access to visit any MJC End User location during normal business hours at HET's sole expense, and in coordination with the
appropriate MJC sales representative, to upgrade or exchange out (with upgraded units) MJC's End User's MedGem devices when and if HET deems appropriate. 

21

 

 
 

EXHIBIT G
  TRAINING AND SUPPORT OBLIGATIONS    
  

        HET shall, during the Term, perform the following training and support obligations: 

	(i)
	HET
will provide to designated MJC personnel, at MJC locations, initial training. Such initial training shall include education on metabolism, resting
metabolic rate, clinical applications, energy balance equations, operation of the MedGem device, and information on BalanceLog and GlucoPilot software features and functionality. All training shall be
scheduled by mutual agreement by the parties and shall be provided in 3-hour training session blocks. Each "training session" is scheduled as 3 consecutive hours during normal
business hours M-F, but may take less than 3 hours to conduct depending upon the composition of the group being trained. MJC shall be responsible for providing all training
facilities and notifying and scheduling the training audience. All training must be scheduled by MJC with HET one month in advance and must be scheduled in full-day (two 3 hour
sessions) increments whenever possible. For training purposes, MJC shall supply disposables for trainings. The initial training shall be provided by HET in two categories: No-Charge
Training and For-Fee Training as specified below.

	(a)
	No-Charge Training—HET shall provide at no charge total of 4 (four) training sessions (up to 3 hours
each) to MJC, with the training sessions performed in mutually agreed upon locations

	(b)
	For-Fee Training—HET shall provide additional training sessions for a fee of $[***] per
hour, per HET trainer and shall be charged in 3-hour block increments plus all HET travel expenses associated with the delivery of such training. All HET trainers shall provide training
using their own equipment, including
the MedGem indirect calorimeter, and MJC will provide all Single Use Breathing Inserts for use in the training session. 

	(ii)
	HET
shall provide to MJC, in written and electronic forms, all standard content of the End User training, instructions for use and misuse, and detailed
standards and information on recommendations, sufficient to enable MJC to perform the obligations of Paragraphs (i), (ii), (v) and (vi) of Exhibit F of this Agreement.

	(iii)
	If
requested by MJC, HET will provide on-going MedGem, BalanceLog and GlucoPilot training beyond the initial training specified above to
MJC personnel on the following basis:

	(a)
	All
on-going training shall be charged at a rate of [***] ($[***]) per hour, per HET trainer, and shall be charged in
3-hour block increments. MJC must provide its own MedGem metabolic measurement device and Single Use Breathing Inserts for use in the training sessions.

	(b)
	All
fees and expenses shall be invoiced by HET and reimbursed by MJC within 30 days of date of invoice.

	(c)
	HET
shall use all reasonable efforts to accommodate the time and place for MJC requested on-going training, but any on-going training shall be scheduled by
mutual agreement of the parties.

	(d)
	In
order to provide reasonable notice to HET of known or anticipated MJC training requirements, MJC agrees to give non-binding good faith training demand forecasts at the
beginning of each month for the following 60 day period during the Term of this Agreement. All forecasts shall be in writing and shall specify the number of attendees and the desired location
and duration. 

22

 

	(iv)
	Customer Support. HET shall provide secondary Customer Support (i.e., customer support to MJC sales reps
and service reps) and primary customer support (i.e., customer support to MJC End Users) to MJC during regular HET customer support hours (currently 8:30am to 5:00pm MST,
Monday—Friday, excluding major holidays) throughout the Hardware Warranty Period or Software Warranty Period, as the case may be. Customer support shall include After the initial warranty
period expires, extended warranties or additional customer service can be purchased at HET standard rates. The products supported by HET Customer Support obligations under this Agreement include the
MedGem indirect calorimeter and the HET BalanceLogTM and GlucoPilot software. HET does not support or troubleshoot any other MJC specific hardware or software, nor any other third party
software or hardware, unless
specifically agreed to and priced by mutual written agreement of the parties. Included in price Exhibit E.

	(v)
	Domestic Aftermarket Support: HET shall maintain all necessary Food and Drug Administration (FDA)
510(k) market clearance necessary to market the MedGemTM by HET. HET shall comply with all regulatory tracking and monitoring requirements for all medical devices sold or otherwise
transferred to MJC for sale or distribution as required by FDA 21 CFR § 820 and the Medical Device Reporting Regulation; this includes all complaint recording, tracking and disposition
including returned material authorizations as required. HET shall investigate, collect and report data to regulatory agencies as required by those agencies to include product recall information,
safety notices, as well as any Current Good Manufacturing Practices (cGMP) documentation that is requested.

	(vi)
	International Aftermarket Support: HET shall obtain all the necessary regulatory clearance required to
market the MedGemTM by HET as a medical device outside the United States prior to supplying products to MJC for distribution in countries other than the United States under the terms of
this Agreement. MJC agrees not to commence marketing or promotional activities, and not to offer the MedGemTM by HET to any potential customer, in non-US locations prior to
receiving written notice from HET that such clearances have been received. Notwithstanding, HET shall comply with all regulatory tracking and monitoring requirements for all medical devices sold or
otherwise transferred to MJC for sale or distribution. HET shall investigate, collect and report data to regulatory agencies as required by those agencies. In the event products are distributed in the
European Union HET's European representative shall investigate, collect and report data to regulatory agencies as required by those agencies. 

23

CONFIDENTIAL TREATMENT REQUESTED

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4),

200.83 and 240.24b-2  

[HealtheTech Letterhead] 

September 24, 2002 

Mead
Johnson & Company

2400 West Lloyd Expressway

Evansville, Indiana 47721-0001 

	Attention:	 	Randall K. Alsman

President, U.S. and Global Business Support

	

Re:	
 	

Amendment to Strategic Partnership Agreement between Mead Johnson & Company ("MJC") and HealtheTech, Inc. ("HET") dated as of August 8,
2002 (the "Agreement").

Dear
Mr. Alsman: 

        This
letter will amend the Agreement as specified below. All capitalized terms used and not defined in this letter shall have the meanings assigned to them in the Agreement. The
Agreement shall continue to be binding except to the extent modified herein. 

        As
we have discussed, although the Agreement provides that MJC shall have the exclusive right, beginning October 1, 2002, to sell HET Products in the Exclusive Markets, MJC will
not be in a position to market or sell the Products until members of its sales force have been trained to sell the Products. The parties currently anticipate that this training will be completed no
later than January 10, 2003 and will be confirmed by written notice from MJC to HET on the date of such completion (the "Product Launch Date"). 

        Accordingly,
MJC and HET have agreed as follows: 

	1.
	Until
the Product Launch Date, HET may sell Products in the Exclusive Markets. These sales will be solicited and made directly by HET and not through any other person or entity. Within
10 business days after each of October 31, November 30, December 31 and the end of each subsequent month until the Product Launch Date, HET shall send MJC a written report
of all sales of Products in the Exclusive Markets during the period since the previous report. Each report will include, for each sale, the institution/customer name, full address, key contact, date
of sale, any customer service comments, and number of each Product sold.

	2.
	Any
sales by HET of MedGem Devices and Breathing Inserts in the Exclusive Markets from October 1, 2002 through the Product Launch Date shall reduce, on a
one-for-one basis, MJC's Take-or-Pay Purchase Commitments for Q1 2003 as set forth in Exhibit B to the Agreement.

	3.
	As
soon as practicable after the Product Launch Date, HET and MJC will cooperate to ensure an orderly transition from HET to MJC of all accounts generated by HET in the Exclusive
Markets pursuant to this letter.

	4.
	MJC
hereby waives, until the Product Launch Date, HET's obligation (in Section 3.4(a) of the Agreement) to refer to MJC all inquiries for purchase of Products received
from within the Markets and Territories. However, HET will provide to MJC by January 1, 2003 relevant information on all inquiries and leads up to that date, and HET will supplement that
information as of the Product Launch Date. 

	5.
	For
the purpose of this Amendment, a sale will be treated as occurring on the date the Product is shipped to the customer. HET shall not make any statement to any prospective customer
in the Exclusive Markets that may lead that party to believe that it may be able to purchase Products after the Product Launch Date for less than [***] dollars
($[***]) for a device or [***] dollars ($[***]) for an insert. 

        Please
indicate your agreement to the terms of this letter by executing where indicated below and returning a copy to us. 

	 	 	Very truly yours,
	

 	
 	

/s/ James R. Mault
	

 	
 	

James R. Mault, MD

Chairman and CEO

ACCEPTED AND AGREED:

MEAD
JOHNSON & COMPANY 

	/s/  RANDALL K. ALSMAN      
 Randall K. Alsman

President, U.S. and Global Business Support	 	 

QuickLinks

EXHIBIT 10.42

MEAD JOHNSON & COMPANY—HEALTHETECH STRATEGIC PARTNERSHIP AGREEMENT

Exhibit A PRODUCT LIST

Exhibit B Purchase Commitments

Exhibit C MARKETS IN TERRITORIES

Exhibit D TRADEMARKS

Exhibit E PRICE LIST

EXHIBIT F MJC OBLIGATIONS

EXHIBIT G TRAINING AND SUPPORT OBLIGATIONSQuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

EXHIBIT 10.43    
  

 
 

HEALTHETECH, INC.
  JAMES MAULT EMPLOYMENT AGREEMENT    
  

        This Agreement is entered into as of September 13, 2002, (the "Effective Date") by and between
HealtheTech, Inc. (the "Company"), and James R. Mault, M.D. ("Executive"). 

        1.    Duties and Scope of Employment.    

        (a)    Positions and Duties.    As of the Effective Date, Executive will continue to serve as Chief Executive Officer
and Chief Medical Officer of the Company. Executive will render such business and professional services in the performance of his duties, consistent with Executive's position within the Company, as
shall reasonably be assigned to him by the Company's Board of Directors (the "Board"). The period of Executive's employment under this Agreement is
referred to herein as the "Employment Term." 

        (b)    Board Membership.    During the Employment Term, Executive will serve as a member and Chairman of the Board,
subject to any required Board and/or stockholder approval. 

        (c)    Obligations.    During the Employment Term, Executive will perform his duties faithfully and to the best of his
ability and will devote his full business efforts and time to the Company. For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation or
consulting activity for any direct or indirect remuneration without the prior approval of the Board; provided, however, that Executive shall be permitted to continue serving as a member of the board
of directors for those corporations in which he is serving in such capacity as of the Effective Date, provided such corporations do not, as of the Effective Date or following the Effective Date,
compete with any business of the Company. 

        2.    At-Will Employment.    The parties agree that Executive's employment with the Company will be
"at-will" employment and may be terminated at any time with or without cause or notice. Executive understands and agrees that neither his job performance nor promotions, commendations,
bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of his employment with the Company. 

        3.    Compensation.    

        (a)    Base Salary.    During the Employment Term, the Company will pay Executive an annual salary of $250,000 as
compensation for his services (the "Base Salary"). The Base Salary will be paid periodically in accordance with the Company's normal payroll practices.
Executive's salary will be subject to review and adjustments will be made based upon the Company's normal performance review practices. 

        (b)    Bonus.    Executive shall be eligible to receive an annual bonus pursuant to the Company's Performance
Management & Annual Bonus Plan (the "Bonus Plan"), which provides that Executive's target bonus equals 40% of the Base Salary (the
"Target Bonus") with the ultimate amount of such bonus based upon the Company's achievement of certain performance targets as provided in the Bonus
Plan. 

        4.    Employee Benefits.    

        (a)    Benefits.    During the Employment Term, Executive (and, if applicable, his eligible dependents) will be
entitled to participate in the employee benefit plans currently and hereafter maintained by the Company of general applicability to other senior executives of the Company, including, without
limitation, the Company's group medical, dental, vision, disability, life insurance, 

1

 

and flexible-spending account plans. The Company reserves the right to cancel or change the benefit plans and programs it offers to its employees at any time. 

        (b)    Key-Man Life Insurance Policy.    The Company currently maintains a key-man life
insurance policy with respect to Executive in the amount of $20,000,000. In the event Executive dies during the Employment Term, the Company shall pay or otherwise direct that $5,500,000 of the
benefit payable to the Company with respect to such policy be paid to Executive's estate. 

        5.    Vacation.    Executive will annually be entitled to five (5) weeks paid vacation in accordance with the
Company's vacation policy, with the timing and duration of specific vacations mutually and reasonably agreed to by the parties hereto. 

        6.    Expenses.    The Company will reimburse Executive for reasonable travel, entertainment or other expenses
incurred by Executive in the furtherance of or in connection with the performance of Executive's duties hereunder, in accordance with the Company's expense reimbursement policy as in effect from time
to time. In addition, the Company will continue to pay Executive's malpractice insurance in an amount at least sufficient to satisfy any coverage requirements under the laws of the State of Colorado,
any medical license fees and any dues for professional, civic and business organizations related to Executive's duties hereunder. 

        7.    Severance.    

        (a)    Termination by Executive for Good Reason or by Company for other than Death, Disability or Cause.    If
(i) Executive terminates his employment with the Company for "Good Reason" (as defined herein), or (ii) the Company terminates Executive's employment with the Company for other than
"Cause" (as defined herein), death or "Disability" (as defined herein), and Executive signs and does not revoke a standard release of claims with the Company in substantially the same form attached
hereto as Exhibit A, then, subject to Section 10, Executive shall be entitled to (A) receive continuing payments of severance pay
at a rate equal to the greater of his Base Salary rate, as then in effect, or $400,000, for a period of twenty-four (24) months from the date of such termination, to be paid
periodically in accordance with the Company's normal payroll policies; (B) a lump-sum payment equal to 100% of Executive's Target Bonus for the year of termination, (C) the
immediate vesting and exercisability of 100% of the shares subject to all of Executive's stock options to purchase Company Common Stock outstanding as of the Effective Date (the
"Stock Options"), and (D) continued payment by the Company of the group health continuation coverage premiums for Executive and Executive's
eligible dependents under Title X of the Consolidated Budget Reconciliation Act of 1985, as amended ("COBRA") as in effect through the lesser of
(x) twenty-four (24) months from the effective date of such termination, (y) the date upon which Executive and Executive's eligible dependents become covered under
similar plans, or (z) the date Executive no longer constitutes a "Qualified Beneficiary" (as such term is defined in Section 4980B(g) of the Internal Revenue Code of 1986, as
amended); provided, however, that Executive will be solely responsible for electing such coverage within the required time periods. 

        (b)    Termination Due to Executive's Disability.    If Executive's employment with the Company terminates due to
Executive's Disability, and Executive (or Executive's personal representative) signs and does not revoke a standard release of claims with the Company, then, subject to Section 10, Executive
shall be entitled to (i) receive continuing payments of severance pay at a rate equal to the greater of his Base Salary rate, as then in effect, or $400,000, for a period of twelve
(12) months from the date of such termination, to be paid periodically in accordance with the Company's normal payroll policies; (ii) a lump-sum payment equal to 100% of
Executive's Target Bonus for the year of termination, and (iii) immediate vesting and exercisability as to the number of shares subject to Stock Options that would have otherwise vested during
the twelve-month period following such termination (that is, in addition to the number of shares that have vested as 

2

 

of such date), but in no event shall the number of shares which so vest exceed the number of shares subject to such Stock Options. 

        (c)    Voluntary Termination within Twelve Months of a Change of Control.    If Executive voluntarily terminates his
employment with the Company without Good Reason within twelve (12) months of a "Change of Control" (as defined herein), then, subject to Executive signing and not revoking a standard release of
claims with the Company and Section 10, Executive shall be entitled to (i) receive continuing payments of severance pay at a rate equal to the greater of his Base Salary rate, as then in
effect, or $400,000, for a period of twelve (12) months from the date of such termination, to be paid periodically in accordance with the Company's normal payroll policies; (ii) a
lump-sum payment equal to 100% of Executive's Target Bonus for the year of termination; and (iii) continued payment by the Company of the group health continuation coverage premiums
for Executive and Executive's eligible dependents under COBRA as in effect through the lesser of (x) twelve (12) months from the effective date of such termination, (y) the date
upon which Executive and Executive's eligible dependents become covered under similar plans, or (z) the date Executive no longer constitutes a Qualified Beneficiary; provided, however, that
Executive will be solely responsible for electing such coverage within the required time periods. 

        (d)    Voluntary Termination; Termination for Cause or Due to Executive's Death.    If (i) Executive
voluntarily terminates his employment with the Company without Good Reason (other than within twelve (12) months of a Change of Control) or (ii) the Company terminates Executive's
employment with the Company for Cause or due to Executive's death, then (A) all vesting of the Stock Options will terminate immediately, (B) all payments of compensation by the Company
to Executive hereunder will terminate immediately (except as to amounts already earned), and (C) Executive will only be eligible for severance benefits in accordance with the Company's
established policies as then in effect, if any. Nothing in this Section 7(d) shall relieve the Company from its obligations provided for in Section 4(b). Notwithstanding
subsection (A) above, if Executive's employment with the Company is terminated due to Executive's death and Executive's estate signs and does not revoke a standard release of claims with
the Company, then Executive's estate shall be entitled to immediate vesting and exercisability as to the number of shares subject to Stock Options that would have otherwise vested during the
twelve-month period following such termination (that is, in addition to the number of shares that have vested as of such date), but in no event shall the number of shares which so vest exceed the
number of shares subject to such Stock Options. 

        8.    Definitions.    

        (a)    Cause.    For purposes of this Agreement, "Cause" is defined as
(i) any act of personal dishonesty taken by Executive in connection with his responsibilities as an employee and intended to result in substantial personal enrichment of Executive,
(ii) the conviction of, or plea of nolo contendere to, a felony which the Board reasonably believes had or will have a material detrimental
effect on the Company's reputation or business, (iii) a willful act by Executive which constitutes gross misconduct and which is injurious to the Company, (iv) continued violations by
Executive of Executive's obligations which are demonstrably willful and deliberate on Executive's part after there has been delivered to Executive a
written demand for performance from the Company which describes the basis for the Company's belief that Executive has not substantially performed his duties, and (v) a material breach by
Executive of Executive's obligations hereunder or the "Confidential Information Agreement" (as defined herein). Any purported termination of Executive for Cause will not be effective until the Company
has delivered to Executive a written explanation which describes the basis for the Company's belief that Executive should be terminated for Cause and Executive has been given thirty (30) days
to cure any curable violation. 

3

 

        (b)    Change of Control.    For purposes of this Agreement, "Change of
Control" of the Company is defined as: 

        (i)    any
"person" (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) is or becomes the "beneficial
owner" (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the
Company's then outstanding voting securities; or 

        (ii)  a
change in the composition of the Board occurring within a two-year period, as a result of which fewer than a majority of the directors are Incumbent
Directors. "Incumbent Directors" will mean directors who either (A) are directors of the Company as of the date hereof, or (B) are
elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but will not include an
individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company); or 

        (iii)  the
date of the consummation of a merger or consolidation of the Company with any other corporation that has been approved by the stockholders of the Company, other
than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being
converted into voting securities of the surviving entity) more than fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity
outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a plan of complete liquidation of the Company; or 

        (iv)  the
date of the consummation of the sale or disposition by the Company of all or substantially all the Company's assets. 

        (c)    Disability.    For purposes of this Agreement, "Disability" is
defined as Executive's inability to substantially perform his essential job functions as the result of a physical or mental disability or incapacity for a period of 180 days, consecutive or
otherwise, in any 360-day period. 

        (d)    Good Reason.    For purposes of this Agreement, "Good Reason"
shall mean without the Executive's express written consent (i) a significant reduction of the Executive's duties, position or responsibilities; (ii) a significant reduction by the
Company in the Base Salary and Target Bonus opportunity of the Executive as in effect immediately prior to such reduction; (iii) a material reduction by the Company in the kind or level of
employee benefits to which the Executive is entitled immediately prior to such reduction with the result that the Executive's overall benefits package is significantly reduced; or (iv) the
relocation of the Executive to a facility or a location more than fifty (50) miles from the Executive's then present location. Any purported termination for by Executive for Good Reason will
not be effective until Executive has delivered to the Company a written explanation which describes the basis for Executive's belief that Executive should be permitted to terminate his employment with
the Company for Good Reason and the Company has been given thirty (30) days to cure any curable violation. 

        9.    Confidential Information and Invention Assignment.    Executive agrees, if he has not already done so, to enter
into the Company's standard Confidential Information and Invention Assignment Agreement (the "Confidential Information Agreement") within a reasonable
time following the Effective Date. Additionally, Executive hereby agrees that any inventions, original works of authorship, developments, concepts, improvements or trade secrets, whether or not
patentable or registrable under copyright or similar laws that relate to the Company's business at the time of his termination from the Company, which Executive may solely or jointly conceive or
develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the six-month period following his 

4

 

termination from the Company will be deemed to be owned by the Company and Executive hereby agrees to hold in trust for the sole right and benefit of the Company, and shall assign to the Company, or
its designee, all of Executive's right, title, and interest in such inventions, original works of authorship, developments, concepts, improvements or trade secrets. 

        10.    Conditional Nature of Severance Payments.    

        (a)    Noncompete.    Executive acknowledges that the nature of the Company's business is such that if Executive were
to become employed by, or substantially involved in, the business of a competitor of the Company during the twenty-four (24) months following the termination of Executive's
employment with the Company, it would be very difficult for Executive not to rely on or use the Company's trade secrets and confidential information. Thus, to avoid the inevitable disclosure of the
Company's trade secrets and confidential information, Executive agrees for a period of twenty-four (24) months following his termination for any reason not to directly or indirectly
engage in (whether as an employee, consultant, agent, proprietor, principal, partner, stockholder, corporate officer, director or otherwise), nor have any ownership interest in or participate in the
financing, operation, management or control of, any person, firm, corporation or business that competes with Company or is a customer of the Company. Notwithstanding the foregoing, Executive shall not
be obligated to comply with the provisions of this
Section 10(a) upon Executive's termination for reasons described in Section 7(a) or (b), provided that Executive acknowledges that Executive's right to receive the
severance payments set forth in Section 7 (to the extent Executive is otherwise entitled to such payments) are contingent upon Executive complying with this Section 10(a) and upon
any breach of this section all severance payments pursuant to this Agreement shall immediately cease and any severance payments or benefits provided to Executive following any
non-compliance with this Section 10(a) shall be immediately reimbursed to the Company. 

        (b)    Non-Solicitation.    Until the date twenty-four (24) months after the
termination of Executive's employment with the Company for any reason, Executive agrees not, either directly or indirectly, to solicit, induce, attempt to hire, recruit, encourage, take away, hire any
employee of the Parent or the Company or cause an employee to leave his or her employment either for Executive or for any other entity or person. Notwithstanding the foregoing, Executive shall not be
obligated to comply with the provisions of this Section 10(b) upon Executive's termination for reasons described in Section 7(a) or (b), provided that Executive acknowledges that
Executive's right to receive the severance payments set forth in Section 7 (to the extent Executive is otherwise entitled to such payments) are contingent upon Executive complying with this
Section 10(b) and upon any breach of this section all severance payments pursuant to this Agreement shall immediately cease and any severance payments or benefits provided to
Executive following any non-compliance with this Section 10(b) shall be immediately reimbursed to the Company. 

        (c)    Understanding of Covenants.    Executive represents that he (i) is familiar with the foregoing covenants
not to compete and not to solicit, and (ii) is fully aware of his obligations hereunder, including, without limitation, the reasonableness of the length of time, scope and geographic coverage
of these covenants. 

        11.    Assignment.    This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors
and legal representatives of Executive upon Executive's death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms
of this Agreement for all purposes. For this purpose, "successor" means any person, firm, corporation or other business entity which at any time,
whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive any form of
compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted 

5

 

assignment, transfer, conveyance or other disposition of Executive's right to compensation or other benefits will be null and void. 

        12.    Notices.    All notices, requests, demands and other communications called for hereunder shall be in writing
and shall be deemed given (i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well established commercial overnight service, or
(iii) four (4) days after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the following addresses, or
at such other addresses as the parties may later designate in writing: 

If
to the Company: 

HealtheTech, Inc.

523 Park Point Drive, 3rd Floor

Golden, CO 80401
 Attn: Vice President, Human Resources; General Counsel 

If
to Executive: 

at
the last residential address known by the Company. 

        13.    Severability.    In the event that any provision hereof becomes or is declared by a court of competent
jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision. 

        14.    Arbitration.    

        (a)    General.    In consideration of Executive's service to the Company, its promise to arbitrate all employment
related disputes and Executive's receipt of the compensation, pay raises and other benefits paid to Executive by the Company, at present and in the future, Executive agrees that any and all
controversies, claims, or disputes with anyone (including the Company and any employee, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising
out of, relating to, or resulting from Executive's service to the Company under this Agreement or otherwise or the termination of Executive's service with the Company, including any breach of this
Agreement, shall be subject to binding arbitration. Disputes which Executive agrees to arbitrate, and thereby agrees to waive any right to a trial by jury, include any statutory claims under state or
federal law, including, but not limited to, claims under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, the Age Discrimination in Employment Act of
1967, the Older Workers Benefit Protection Act, claims of harassment, discrimination or wrongful termination and any statutory claims. Executive further understands that this Agreement to arbitrate
also applies to any disputes that the Company may have with Executive. 

        (b)    Procedure.    Executive agrees that any arbitration will be administered by the American Arbitration
Association ("AAA") and that a neutral arbitrator will be selected in a manner consistent with its National Rules for the Resolution of
Employment Disputes. The arbitration proceedings will allow for discovery according to the rules set forth in the National Rules for the Resolution of Employment
Disputes. Executive agrees that the arbitrator shall have the power to decide any motions brought by any party to the arbitration, including motions for summary judgment and/or
adjudication and motions to dismiss and demurrers, prior to any arbitration hearing. Executive agrees that the arbitrator shall
issue a written decision on the merits. Executive also agrees that the arbitrator shall have the power to award any remedies, including attorneys' fees and costs, available under applicable law.
Executive understands the Company will pay for any administrative or hearing fees charged by the arbitrator or AAA except that Executive shall pay the first $200.00 of any filing fees associated with
any arbitration Executive initiates. 

6

 

        (c)    Remedy.    Except as provided by the Rules, arbitration shall be the sole, exclusive and final remedy for any
dispute between Executive and the Company. Accordingly, neither Executive nor the Company will be permitted to pursue court action regarding claims that are subject to arbitration. Notwithstanding,
the arbitrator will not have the authority to disregard or refuse to enforce any lawful Company policy, and the arbitrator shall not order or require the Company to adopt a policy not otherwise
required by law which the Company has not adopted. 

        (d)    Availability of Injunctive Relief.    Executive agrees that either party may also petition the court for
injunctive relief where either party alleges or claims a violation of this Agreement or the Confidential Information Agreement or any other agreement regarding trade secrets, confidential information,
and nonsolicitation. In the event either party seeks injunctive relief, the prevailing party shall be entitled to recover reasonable costs and attorneys' fees. 

        (e)    Administrative Relief.    Executive understands that this Agreement does not prohibit Executive from pursuing
an administrative claim with a local, state or federal administrative body. This Agreement does, however, preclude Executive from pursuing court action regarding any such claim. 

        (f)    Voluntary Nature of Agreement.    Executive acknowledges and agrees that Executive is executing this Agreement
voluntarily and without any duress or undue influence by the Company or anyone else. Executive further acknowledges and agrees that Executive has carefully read this Agreement and that Executive has
asked any questions needed for Executive to understand the terms, consequences and binding effect of this Agreement and fully understand it, including that Executive is waiving Executive's right to a
jury trial. Finally, Executive agrees that Executive has been provided an opportunity to seek the advice of an attorney of Executive's choice before signing this Agreement. 

        15.    Integration.    This Agreement, together with the Bonus Plan, any plans or agreements relating to the Stock
Options and the Confidential Information Agreement, represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous
agreements whether written or oral. No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless it is in writing and specifically mentions this
Section 15 and it is signed by duly authorized representatives of the parties hereto. 

        16.    Legal Fees.    The Company and Executive both agree that each is responsible for its or his own attorneys' fees
incurred in connection with the negotiation, preparation, implementation and execution of this Agreement. 

        17.    Waiver of Breach.    The waiver of a breach of any term or provision of this Agreement, which must be in
writing, shall not operate as or be construed to be a waiver of any other previous or subsequent breach of this Agreement. 

        18.    Headings.    All captions and section headings used in this Agreement are for convenient reference only
and do not form a part of this Agreement. 

        19.    Tax Withholding.    All payments made pursuant to this Agreement will be subject to withholding of applicable
taxes. 

        20.    Governing Law.    This Agreement will be governed by the laws of the State of Colorado (with the exception of
its conflict of laws provisions). 

        21.    Acknowledgment.    Executive acknowledges that he has had the opportunity to discuss this matter with and
obtain advice from his private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily entering into
this Agreement. 

7

 

        22.    Counterparts.    This Agreement may be executed in counterparts, and each counterpart shall have the same force
and effect as an original and shall constitute an effective, binding agreement on the part of each of the undersigned. 

        IN
WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by their duly authorized officers, as of the day and year first above written. 

	

COMPANY:	
 	

 	

 
	

HEALTHETECH, INC.	
 	

 	

 
	

/s/  NOEL JOHNSON      
	
 	

Date:	

September 13, 2002

	By:	Noel Johnson	 	 	 
	Title:	President & COO	 	 	 
	

EXECUTIVE:	
 	

 	

 
	

/s/  JAMES R. MAULT      
	
 	

Date:	

September 13, 2002

	James R. Mault, M.D.	 	 	 

8

  

 
 

EXHIBIT A    
  

 
  SEVERANCE AGREEMENT AND RELEASE    
  

RECITALS  

        This Severance Agreement and Release ("Agreement") is made by and between James Mault ("Employee") and HealtheTech, Inc. (the "Company") (collectively
referred to as the "Parties"): 

        WHEREAS,
Employee was employed by the Company; 

        WHEREAS,
the Company and Employee entered into an employment agreement dated                        (the "Employment Agreement");

        WHEREAS,
the Company and Employee entered into a [CLICK AND TYPE exact title of proprietary information agreement Employee signed] (the "Confidentiality
Agreement"); 

        WHEREAS,
[reference equity related agreements for Jim.]; [e.g. the Company and Employee have entered
into a Stock Option Agreement dated [Click And Type Date] (the "Option Agreement") granting Employee the option (the "Option") to purchase shares of the Company's common stock
subject to the terms and conditions of the Company's [Click And Type Year] Stock Option Plan (the "Plan");] 

        WHEREAS,
Employee's employment with Company was terminated on or about [Click And Type Date] (the "Termination Date"); 

        WHEREAS,
the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions and demands that Employee may have against the Company as defined
herein, including, but not limited to, any and all claims arising or in any way related to Employee's employment with, or separation from, the Company; 

        NOW
THEREFORE, in consideration of the promises made herein, the Parties hereby agree as follows: 

 
 

COVENANTS    
  

        1.    Consideration.    Pursuant to the terms of Section 7(    ) of the Employment Agreement, upon
the Effective Date of this Agreement, Executive shall be entitled to the following: 

        (a)  The
Company agrees to pay Employee continuing payments of severance pay at a rate equal to his "Base Salary" (as defined in the Employment Agreement) rate, as then in
effect, for a period of [twenty-four (24)/twelve (12)] months from the Termination Date, to be paid
periodically in accordance with the Company's normal payroll policies. 

        (b)  [The Company agrees a lump-sum payment equal to 100% of Executive's "Target Bonus" (as defined in the Employment
Agreement) for the year of the Termination Date.]  

        (c)    Options.    [One hundred percent (100%) of the
shares subject to the Options shall immediately vest and become exercisable.] [The Options shall immediately vest as to the number of shares that would have otherwise vested
had Employee continued as an employee of the Company until twelve (12) months following the Termination Date.] Except as expressly stated herein, the Options
shall be exercisable in accordance with the terms of the Plan and the Option Agreements.] 

        (d)    [Continued Employee
Benefits.    The Company will provide Employee with health, dental and vision benefits coverage during the
[twenty-four (24)/twelve (12)] month period beginning on the Termination Date, but only if Employee elects continuation coverage under the Consolidated Omnibus
Budget Reconciliation Act of 1985, as amended ("COBRA"), within the time period  

1

 

 prescribed pursuant to COBRA. For the duration of the [twenty-four (24)/twelve (12)] month period, the Company will pay the COBRA premiums otherwise payable by
Employee (and Employee's eligible dependents). After the [twenty-four (24)/twelve (12)] month period, Employee will be responsible for the payment of any COBRA
premiums.]  

        2.    Confidential Information and Invention Assignment.    Employee shall continue to
maintain the confidentiality of all confidential and proprietary information of the Company and shall continue to comply with the terms and conditions of the Confidentiality Agreement between Employee
and the Company. Additionally, Employee hereby acknowledges his obligations set forth in Section 9 of the Employment Agreement regarding inventions, original works of authorship, developments,
concepts, improvements or trade secrets, whether or not patentable or registrable under copyright or similar laws that relate to the Company's business as of the Termination Date. Employee shall
return all of the Company's property and confidential and proprietary information in his possession to the Company on the Effective Date of this Agreement. 

        3.    Payment of Salary.    Employee acknowledges and represents that the Company has paid all salary, wages, bonuses,
accrued vacation, commissions and any and all other benefits due to Employee once the above noted payments and benefits are received. 

        4.    Release of Claims.    Employee agrees that the foregoing consideration represents settlement in full of all
outstanding obligations owed to Employee by the Company and its officers, managers, supervisors, agents and employees. Employee, on his own behalf, and on behalf of his respective heirs, family
members, executors, agents, and assigns, hereby fully and forever releases the Company and its officers, directors, employees, agents, investors, shareholders, administrators, affiliates, divisions,
subsidiaries, predecessor and successor corporations, and assigns, from, and agree not to sue concerning, any claim, duty, obligation or cause of action relating to any matters of any kind, whether
presently known or unknown, suspected or unsuspected, that Employee may possess arising from any omissions, acts or facts that have occurred up until and including the Effective Date of this Agreement
including, without limitation: 

        (a)  any
and all claims relating to or arising from Employee's employment relationship with the Company and the termination of that relationship; 

        (b)  any
and all claims relating to, or arising from, Employee's right to purchase, or actual purchase of shares of stock of the Company, including, without limitation, any
claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law; 

        (c)  any
and all claims under the law of any jurisdiction including, but not limited to, wrongful discharge of employment; constructive discharge from employment; termination
in violation of public policy; discrimination; breach of contract, both express and implied; breach of a covenant of good faith and fair dealing, both express and implied; promissory estoppel;
negligent or intentional infliction of emotional distress; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair
business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; and conversion; 

        (d)  any
and all claims for violation of any federal, state or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964, the Civil
Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, the Fair Labor Standards Act, the Employee Retirement Income Security Act of 1974,
the Worker Adjustment and Retraining Notification Act, Older Workers Benefit Protection Act; the California Fair Employment and Housing Act, and the California Labor Code, the Colorado
Anti-Discrimination Act, the Colorado Wage Claim Act, the Colorado Equal Pay Law, the 

2

 

Adoptive Parents Leave Act, Colorado common law and any and all other state, county or local ordinances, statutes or regulations; 

        (e)  any
and all claims for violation of the federal, or any state, constitution; 

          (f)  any
and all claims arising out of any other laws and regulations relating to employment or employment discrimination; 

        (g)  any
claim for any loss, cost, damage, or expense arising out of any dispute over the non-withholding or other tax treatment of any of the proceeds received
by Employee as a result of this Agreement; and 

        (h)  any
and all claims for attorneys' fees and costs. 

        The
Company and Employee agree that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released.
This release does not extend to any obligations incurred under this Agreement. 

        5.    Breaches by Employee.    Employee acknowledges and agrees that any breach of any provision of this Agreement or
Sections 9 or 10 of the Employment Agreement shall constitute a material breach of this Agreement or the Employment Agreement, as applicable, and shall entitle the Company immediately to
recover and cease the severance benefits provided to Employee under this Agreement. 

        6.    [Acknowledgement of Waiver of Claims Under
ADEA.    Employee acknowledges that he is waiving and releasing any rights he may have under the Age Discrimination in Employment Act of 1967
("ADEA") and that this waiver and release is knowing and voluntary. Employee and the Company agree that this waiver and release does not apply to any rights or claims that may arise under ADEA after
the Effective Date of this Agreement. Employee acknowledges that the consideration given for this waiver and release Agreement is in addition to anything of value to which Employee was already
entitled. Employee further acknowledges that he has been advised by this writing that:  

         (a)  he should consult with an attorney prior to executing this Agreement;

        (b)  he has up to twenty-one (21) days within which to consider this Agreement;  

        (c)  he has seven (7) days following his/her execution of this Agreement to revoke this Agreement;

        (d)  this Agreement shall not be effective until the revocation period has expired; and

        (e)  nothing in this Agreement prevents or precludes Employee from challenging or seeking a determination in good faith of the validity of this waiver
under the ADEA, nor does it impose any condition precedent, penalties or costs for doing so, unless specifically authorized by federal law.]  

        7.    Civil Code Section 1542.    The Parties represent that they are not aware of any
claim by either of them other than the claims that are released by this Agreement. Employee acknowledges that he has had the opportunity to seek the advice of legal counsel and is familiar with the
provisions of California Civil Code Section 1542, which provides as follows: 

A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED
HIS SETTLEMENT WITH THE DEBTOR. 

        Employee,
being aware of said code section, agrees to expressly waive any rights he may have thereunder, as well as under any other statute or common law principles of similar effect. 

        8.    No Pending or Future Lawsuits.    Employee represents that he has no lawsuits, claims, or actions pending in his
name, or on behalf of any other person or entity, against the Company or any 

3

 

other person or entity referred to herein. Employee also represents that he does not intend to bring any claims on his own behalf or on behalf of any other person or entity against the Company or any
other person or entity referred to herein. 

        9.    Application for Employment.    Employee understands and agrees that, as a condition of this Agreement, he shall
not be entitled to any employment with the Company, its subsidiaries, or any successor, and he hereby waives any right, or alleged right, of employment or re-employment with the Company,
its subsidiaries or related companies, or any successor. 

        10.    Confidentiality.    The Parties acknowledge that Employee's agreement to keep the terms and conditions of this
Agreement confidential was a material factor on which all parties relied in entering into this Agreement. Employee hereto agrees to use his best efforts to maintain in confidence: (i) the
existence of this Agreement, (ii) the contents and terms of this Agreement, (iii) the consideration for this Agreement, and (iv) any allegations relating to the Company or its
officers or employees with respect to Employee's employment with the Company, except as otherwise provided for in this Agreement (hereinafter collectively referred to as "Settlement Information").
Employee agrees to take every reasonable precaution to prevent disclosure of any Settlement Information to third parties, and agrees that there will be no publicity, directly or indirectly, concerning
any Settlement Information. Employee agrees to take every precaution to disclose Settlement Information only to those attorneys, accountants, governmental entities, and family members who have a
reasonable need to know of such Settlement Information. 

        11.    No Admission of Liability.    The Parties understand and acknowledge that this Agreement constitutes a
compromise and settlement of disputed claims. No action taken by the Parties hereto, or either of them, either previously or in connection with this Agreement shall be deemed or construed to be:
(a) an admission of the truth or falsity of any claims heretofore made or (b) an acknowledgment or admission by either party of any fault or liability whatsoever to the other party or to
any third party. 

        12.    No Knowledge of Wrongdoing.    Employee represents that he has no knowledge of any wrongdoing involving
improper or false claims against a federal or state governmental agency, or any other wrongdoing that involves Employee or other present or former Company employees. 

        13.    Costs.    The Parties shall each bear their own costs, expert fees, attorneys' fees and other fees incurred in
connection with this Agreement. 

        14.    Indemnification.    Employee agreed to indemnify and hold harmless the Company from and against any and all
loss, costs, damages or expenses, including, without limitation, attorneys' fees or expenses
incurred by the Company arising out of the breach of this Agreement by Employee, or from any false representation made herein by Employee, or from any action or proceeding which may be commenced,
prosecuted or threatened by Employee or for Employee's benefit, upon Employee's initiative, or with Employee's aid or approval, contrary to the provisions of this Agreement. Employee further agrees
that in any such action or proceeding, this Agreement may be pled by the Company as a complete defense, or may be asserted by way of counterclaim or cross-claim. 

        15.    Arbitration.    The Parties agree that any and all disputes arising out of, or relating to, the terms of this
Agreement, their interpretation, and any of the matters herein released, shall be subject to binding arbitration in [County]
before the American Arbitration Association under its National Rules for the Resolution of Employment Disputes. The Parties agree that the prevailing party in any arbitration shall be entitled
to injunctive relief in any court of competent jurisdiction to enforce the arbitration award. The Parties agree that the prevailing party in any arbitration shall be awarded its reasonable attorneys'
fees and costs. The Parties hereby agree to waive their right to have any dispute between them resolved in a court of law by a judge or jury. This
section will not prevent either party from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over 

4

 

the Parties and the subject matter of their dispute relating to Employee's obligations under this Agreement and the agreements incorporated herein by reference. 

        16.    Authority.    The Company represents and warrants that the undersigned has the authority to act on behalf of
the Company and to bind the Company and all who may claim through it to the terms and conditions of this Agreement. Employee represents and warrants that he has the capacity to act on his own behalf
and on behalf of all who might claim through him to bind them to the terms and conditions of this Agreement. Each party warrants and represents that there are no liens or claims of lien or assignments
in law or equity or otherwise of or against any of the claims or causes of action released herein. 

        17.    No Representations.    Each Party represents that it has had the opportunity to consult with an attorney, and
has carefully read and understands the scope and effect of the provisions of this Agreement. Neither Party has relied upon any representations or statements made by the other Party hereto which are
not specifically set forth in this Agreement. 

        18.    Severability.    In the event that any provision hereof becomes or is declared by a court of competent
jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision so long as the remaining provisions remain intelligible and continue to
reflect the original intent of the Parties. 

        19.    Entire Agreement.    This Agreement represents the entire agreement and understanding between the Company and
Employee concerning the subject matter of this Agreement and Employee's relationship with the Company, and supersedes and replaces any and all prior agreements and understandings between the Parties
concerning the subject matter of this Agreement and Employee's relationship with
the Company, with the exception of the Confidentiality Agreement the Plan, the Option Agreements, and Sections 9 and 10 of the Employment Agreement. 

        20.    No Waiver.    The failure of any party to insist upon the performance of any of the terms and conditions in
this Agreement, or the failure to prosecute any breach of any of the terms and conditions of this Agreement, shall not be construed thereafter as a waiver of any such terms or conditions. This entire
Agreement shall remain in full force and effect as if no such forbearance or failure of performance had occurred. 

        21.    No Oral Modification.    Any modification or amendment of this Agreement, or additional obligation assumed by
either party in connection with this Agreement, shall be effective only if placed in writing and signed by both Parties or by authorized representatives of each Party. 

        22.    Governing Law.    This Agreement shall be deemed to have been executed and delivered within the State of
Colorado, and it shall be construed, interpreted, governed, and enforced in accordance with the laws of the State of Colorado, without regard to conflict of law principles. To the extent that either
party seeks injunctive relief in any court having jurisdiction for any claim relating to the alleged misuse or misappropriation of trade secrets or confidential or proprietary information, each party
hereby consents to personal and exclusive jurisdiction and venue in the state and federal courts of the State of Colorado. 

        23.    Attorneys' Fees.    In the event that either Party brings an action to enforce or effect its rights under this
Agreement, the prevailing party shall be entitled to recover its costs and expenses, including the costs of mediation, arbitration, litigation, court fees, plus reasonable attorneys' fees, incurred in
connection with such an action. 

        24.    Effective Date.    This Agreement is effective after it has been signed by both Parties  [and after eight (8) days have passed since Employee
has signed the Agreement] (the "Effective Date"). 

5

 

        25.    Counterparts.    This Agreement may be executed in counterparts, and each counterpart shall have the same force
and effect as an original and shall constitute an effective, binding agreement on the part of each of the undersigned. 

        26.    Voluntary Execution of Agreement.    This Agreement is executed voluntarily and without any duress or undue
influence on the part or behalf of the Parties hereto, with the full intent of releasing all claims. The Parties acknowledge that: 

        (a)  They
have read this Agreement; 

        (b)  They
have been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of their own choice or that they have voluntarily declined
to seek such counsel; 

        (c)  They
understand the terms and consequences of this Agreement and of the releases it contains; and 

        (d)  They
are fully aware of the legal and binding effect of this Agreement. 

[Remainder of Page Intentionally Left Blank]

6

 

        IN
WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth below. 

	

 	
 	

HealtheTech, Inc.
	

Dated:	
 	

By	

        
 [Click and Type Officer Name]

[Click and Type Title]
	

 	
 	

James Mault, an individual
	

Dated:	
 	

 James Mault

7

QuickLinks

EXHIBIT 10.43

HEALTHETECH, INC. JAMES MAULT EMPLOYMENT AGREEMENT

EXHIBIT A

SEVERANCE AGREEMENT AND RELEASE

COVENANTS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}]]